



ABN: 97 084 464 193

Suite 1 A, Level 2
802 Pacific Highway
Gordon NSW 2072

P: +61 2 9844 5422
F: +61 2 9844 5445



**Australian Securities Exchange Limited
Companies Announcements Office
SYDNEY**

12 November 2012

Bioxyne's board renewal focuses on creating shareholder value

Bioxyne Limited (ASX: BXN) is pleased to advise that it had reconstituted its board of directors following the Company's EGM where shareholders elected a new non-executive director, and removed two non-executive directors.

Mr Anthony Ho was elected as non-executive director. Mr Ho is an experienced director and non-executive chairman of several listed and unlisted companies in the mining and finance sector.

Mr Ho's extensive corporate finance and governance experience included being past Chief Financial Officer/Finance Director of M. S. McLeod Holdings Limited, Galore Group Limited, Edward H O'Brien group of companies and Volante Group Limited. Prior to joining commerce, Mr Ho was a partner of Cox Johnston & Co, Chartered Accountants which has since merged with Ernst & Young.

Mr Ho holds a Bachelor of Commerce degree from the University of New South Wales and is a member of the Institute of Chartered Accountants in Australia and a fellow of both the Chartered Institute of Company Secretaries and the Australian Institute of Company Directors. Mr Ho will also chair the Company's Audit and Risk Committee.

Bioxyne Chairman Ian Mutton said, "The new Bioxyne board is united and enthusiastic about the significant opportunities that lie ahead for the business. We are now focused on executing our strategy of commercialising the Australian-invented HI-164 therapy for chronic obstructive pulmonary disease (COPD).

"At the same time, the Board continues to actively review other commercial assets that could enhance shareholder value in parallel with the new study into the clinical efficacy of HI-164 in partnership with the internationally respected Australian-based developer Vaxine Limited led by Professor Nikolai Petrovsky. The board remains firmly focused on



ABN: 97 084 464 193

Suite 1 A, Level 2
802 Pacific Highway
Gordon NSW 2072

P: +61 2 9844 5422
F: +61 2 9844 5445



creating long term value for shareholders and executing on its operating and growth plans,” Mr Mutton said.

The Bioxyne board is presently, Chairman Ian Mutton, CEO David Radford, William Harrison, Patrick Ford and Anthony Ho.

The Chief Financial Officer and Company Secretary is Ashok Jairath.

For Further information please contact:

David Radford

Chief Executive Officer

Tel: +61 (0) 407-218-922

Tim Allerton or Andrew Geddes

CityPR

(02) 9267 4511

About Bioxyne

Bioxyne Limited (ASX:BXN) is an Australian immunotherapeutics business commercialising a new therapy for patients with Chronic Obstructive Pulmonary Disease (COPD). Its lead product HI-164 is based on the proprietary technology that uses the application of mucosal immunology to treat common human diseases. HI-164 works by controlling bacterial infections of airways damaged by toxins. HI-164 recently completed a Phase IIb clinical trial for COPD where it was shown to be effective in a subset of the patient cohort under the age of 65. The company is planning a new study to further investigate the findings from this study.

Chronic Obstructive Pulmonary Disorder

COPD is a disease largely caused by smoking but with a rising number of new cases caused by pollution in developing countries. The global incidence of COPD, which includes common diseases like bronchitis and emphysema, is growing rapidly and is a substantial burden on health budgets worldwide. An analysis by the Australian Lung Foundation in 2008 indicated the wide economic cost of to the Australian economy in 2010 was estimated to be \$9 billion in direct and indirect costs, with \$1 billion incurred in direct health system expenditure. There are currently no effective treatments for COPD and 25 per cent of COPD patients admitted to hospital die within one year. Reducing hospital admissions is crucial and preventing exacerbations is the main choice of therapy. It is estimated COPD will be third leading cause of mortality in the next decade, behind heart failure and cancer. COPD is Australia’s second leading cause of avoidable hospital admissions .